Activate Now
 
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY RESULTS: Medical Marijuana

Decreased levels of vitamin D associated with reduced methylation in African American teens

Recipe: Mega-Golden Milk

Sweep Away Senile Cells

PAIN'S SECRET MESSAGE: Why Prince Didn't Need to Die

8 Hacks to Slash Medication Costs

Relief from Common Digestive Distress

New Study Shows Optimized Curcumin Stops Inflammation

Block The Vascular Origins Of Cognitive Decline

Selenium - What Is it and Where Do I Get It?

 
Print Page
Email Article

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: A randomized phase II trial - Source: The Lancet Neurology, June 2008

  [ 152 votes ]   [ Discuss This Article ]
By Gordon K Wilcock, DM, et al. • www.ProHealth.com • June 2, 2008


[Note: this study involved 207 patients. Results of a larger study involving 1800 patients with mild Alzheimer’s expected in 2008.]

Background: The amyloid-ß peptide Aß42 has been implicated in the pathogenesis of Alzheimer's disease (AD). We aimed to test the effects of tarenflurbil [trade name FlurizanTM], a selective Aß42-lowering agent (SALA), on cognition and function in patients with mild to moderate AD.

Methods: 210 patients living in the community who had a mini-mental state examination (MMSE) score of 15-26 were randomly assigned to receive tarenflurbil twice per day (400 mg [n=69] or 800 mg [n=70]) or placebo (n=71) for 12 months in a phase II, multicenter, double-blind study.

Primary efficacy outcomes were the AD assessment scale cognitive subscale (ADAS-cog), the Alzheimer's Disease Cooperative Study activities of daily living scale (ADCS-ADL), and the clinical dementia rating sum of boxes (CDR-sb).

In a 12-month extended treatment phase, patients who had received tarenflurbil continued to receive the same dose, and patients who had received placebo were randomly assigned to tarenflurbil at 800 mg or 400 mg twice per day.

Primary efficacy analyses were done by intention to treat. This trial is registered with Health Canada (084527) and the Medicines and Healthcare products Regulatory Agency in the UK (20365/0001/A 69316).

Findings: A prespecified interaction analysis revealed that patients with mild AD (baseline MMSE 20-26) and moderate AD (baseline MMSE 15-19) responded differently to tarenflurbil in the ADAS-cog and the ADCS-ADL (p=0•10); therefore, these groups were analyzed separately.

Patients with mild AD in the 800 mg tarenflurbil group had lower rates of decline than did those in the placebo group in activities of daily living (ADCS-ADL difference in slope 3•98 [95% CI 0•33 to 7•62] points per year, effect size [reduction from placebo decline rate] 46.4%, Cohen's d 0•45; p=0•033) and global function (CDR-sb difference -0•80 [-1•57 to -0•03] points per year, effect size 35•7%, Cohen's d 0•42; p=0•042); slowing of cognitive decline did not differ significantly (ADAS-cog difference -1•36 [-4.07 to 1.36] points per year, effect size 33.7%, Cohen's d 0•20; p=0•327).

In patients with moderate AD, 800 mg tarenflurbil twice per day had no significant effects on ADCS-ADL and ADAS-cog and had a negative effect on CDR-sb (-52%, Cohen's d -1•08; p=0•003). The most common adverse events were diarrhea (in seven, nine, and five patients in the 800 mg, 400 mg, and placebo groups, respectively), nausea (in seven, seven, and four patients), and dizziness (in five, nine, and four patients).

Patients with mild AD who were in the 800 mg tarenflurbil group for 24 months had lower rates of decline for all three primary outcomes than did patients who were in the placebo group for months 0-12 and a tarenflurbil group for months 12-24 (all p<.0001), and had better outcomes than did patients who were in the placebo group for months 0-12 and the 800 mg tarenflurbil group for months 12-24 (all p<0•05).

Interpretation: 800 mg tarenflurbil twice per day was well tolerated for up to 24 months of treatment, with evidence of a dose-related effect on measures of daily activities and global function in patients with mild AD.

Funding: Myriad Pharmaceuticals.

Source: The Lancet Neurology, June 2008. 7(6):483-493 PMID: 18450517, by Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. University of Oxford, John Radcliffe Hospital, Oxford, UK. Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada; Myriad Pharmaceuticals, Salt Lake City, Utah, USA. [E-mail: gordon.wilcock@ndm.ox.ac.uk]





Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Optimized Curcumin Longvida® Vitamin D3 Extreme™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
20 Helpful Tips for Cleaning and Organizing When You're Chronically Ill

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

The Fast-Acting Solution for Healthy Digestive Function The Fast-Acting Solution for Healthy Digestive Function
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH
Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits
Could a B-12 Deficiency Be Causing Your Symptoms? Could a B-12 Deficiency Be Causing Your Symptoms?
Priming Your Immune System for Cold & Flu Season Priming Your Immune System for Cold & Flu Season

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler

· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map